Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy
NCT ID: NCT01209988
Last Updated: 2010-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
220 participants
INTERVENTIONAL
2010-04-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tamsulosin 0.4mg
Perioperative tamsulosin 0.4mg daily
tamsulosin 0.4mg
perioperative tamsulosin 0.4mg daily for three weeks
Control
No medication
No medication
No medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tamsulosin 0.4mg
perioperative tamsulosin 0.4mg daily for three weeks
No medication
No medication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must receive robot assisted laparoscopic radical prostatectomy
* Patients must be able to provide written informed consent
Exclusion Criteria
* Patients must not have previously undergone transurethral resection, laser therapy, or other surgery of the prostate
* Patients must not have previously been diagnosed with neurogenic bladder
* Patients must not have hypersensitivity to trial drug or other alpha-blockers
* Patients must not have the participation of other clinical trial within the past 3 months
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asan Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Choung-Soo Kim, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Urology, Asan Medical Center, Seoul, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMC_UR_010
Identifier Type: -
Identifier Source: org_study_id